Overview

Safety and Efficacy of Vanoxerine for Conversion of Atrial Fibrillation or Flutter to Normal Sinus Rhythm

Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
Evaluate the safety and efficacy of a single oral dose of vanoxerine compared to placebo, in a dose modification manner, on the conversion of symptomatic atrial fibrillation (a-fib) or flutter of recent onset to normal sinus rhythm.
Phase:
Phase 2
Details
Lead Sponsor:
Laguna Pharmaceuticals, Inc.
Treatments:
Vanoxerine